UK study tests new preventative therapy for contagious gut infection

The first patient globally has been recruited to test a new preventative therapy into the life-threatening and contagious gut infection, C. difficile. The study was accelerated through the UK Vaccine Innovation Pathway (VIP) – an initiative hosted by the NIHR and part of the UKCRD programme – and was set up in just 86 days.